Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes~* BMI 20-45kg/m2 inclusive~Exclusion Criteria:~* females who are pregnant, lactating or \<6 weeks post-partum~* current symptomatic heart failure (NYHA Class III or IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- albiglutide + metformin (Type: EXPERIMENTAL): Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
- sitagliptin + metformin (Type: ACTIVE_COMPARATOR): Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
- glimepiride + metformin (Type: ACTIVE_COMPARATOR): Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
- metformin + placebo (Type: ACTIVE_COMPARATOR): Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride

Based on this trial design, predict the completion outcome and termination type (if applicable).